comment: >
  
  Wait, I thought all previous Alzheimer research related to this method was deemed to possibly be fake?
context: Lecanemab, a monoclonal antibody, is not a cure but works by binding to amyloid beta, a hallmark of Alzheimer’s disease. In late November, results from an 18-month Phase 3 clinical trial published in The New England Journal of Medicine showed that lecanemab “reduced markers of amyloid in early Alzheimer’s disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events.”
  
  seems to be treating down stream effects of Alzheimer’s and isn’t yet close enough to treating the early mechanisms of the disease, but if it buys some time and becomes one of many new tools in our belt where previously there were none, huzzah! >
  
  Yeah, each of these drugs is a step to developing new treatments by revealing information that may not have been previously visible. >
  
  That is more of a problem with poorly presented science media coverage. >
  
  however, media coverage shouldn't sway the approval or not, but in this case it might have >
  
  Glad they gave it an easy-to-remember name. >
  
  It looks like it was purposefully written backwards. >
  
  Yeah, and it's equally confusing both ways.
  They may as well have gone with a Klingon palindrome. >
  
  Maybe they’re trying to induce dementia by confusing people. >
  
  This drug is like treating diarrhea by cleaning the soiled underwear. >
  
  I regret that I have only upvote for you, because that's as apt a characterization of these 'plaque removing' drugs as I've seen ;). >
  
  Tiny improvements, but not even beginning to be a useful treatment. Baby steps, I guess... >
  
  But at a huge cost.  Every one of these drugs has the potential to jack up everyone’s Medicare premiums by noticeable amounts.  The last thing fixed-income seniors need are baby steps to baby steps that cost an extra $22 a month per step. >
  
  That's how socialized medicine works.  It spreads the cost out >
  
  That’s why you don’t blindly apply cost spreading even in socialism.  The way these drugs are funded is unsustainable. >
  
  How would you reform the process? >
  
  how does lecanemab differ from simufilam? >
  
  Different mechanisms of action with similar effects. Simufilam also appears to be significantly more tolerable, although it still hasn't completed all of its trials.
  Judging by the data, simufilam is the safer and more effective drug, however, it should be noted that the developer's claims have been met with skepticism.